Highlights
- EPS (TTM)
- $14.78
- PE Ratio
- 6.43
- PEG Ratio
- 0.05
- Total Revenue (TTM)
- $875.26M
- Gross Profit (TTM)
- $444.28M
- EBITDA (TTM)
- $274.31M
- Year Range
- $65.50 - $193.07
- Target Price
- $205.00
- ROA (TTM)
- 6.99%
- ROE (TTM)
- 15.16%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Nutex Health Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Nutex Health Inc (NUTX) has returned -42.27% so far this year and 102.08% over the past 12 months.
Nutex Health Inc
- 1D
- 4.55%
- 1M
- -13.96%
- YTD
- -42.27%
- 6M
- -8.01%
- 1Y
- 102.08%
- 3Y*
- -14.40%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Apr 4, 2022, NUTX's average daily return is -0.07%, while the average monthly return is +0.56%. At this rate, your investment would double in approximately 10.3 years.
Historically, 40% of months were positive and 60% were negative. The best month was Aug 2024 with a return of +168.9%, while the worst month was Apr 2022 at -76.5%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.
On a daily basis, NUTX closed higher 46% of trading days. The best single day was Apr 26, 2022 with a return of +73.8%, while the worst single day was Apr 5, 2022 at -33.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -9.62% | -25.76% | -13.96% | -42.27% | |||||||||
| 2025 | 50.30% | 15.26% | -14.34% | 133.83% | 52.53% | -25.78% | -31.87% | -1.20% | 23.31% | 19.11% | -6.46% | 43.01% | 419.47% |
| 2024 | -27.78% | -13.08% | -15.13% | -57.94% | 12.81% | -12.84% | 33.72% | 168.89% | 1.45% | 2.72% | 66.89% | -14.81% | 17.37% |
| 2023 | -29.47% | 2.24% | -26.28% | -43.74% | -23.39% | -3.15% | -0.76% | -33.82% | -26.87% | 2.22% | -8.12% | -5.36% | -90.53% |
| 2022 | -76.45% | 5.94% | -67.69% | -18.14% | 1.89% | -44.24% | -46.33% | 92.55% | 22.58% | -95.25% |
Benchmark Metrics
Nutex Health Inc has an annualized alpha of -27.91%, beta of 1.48, and R² of 0.04 versus S&P 500 Index. Calculated based on daily prices since April 05, 2022.
- This stock participated in 239.78% of S&P 500 Index downside but only -19.04% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.04 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -27.91%
- Beta
- 1.48
- R²
- 0.04
- Upside Capture
- -19.04%
- Downside Capture
- 239.78%
Return for Risk
Risk / Return Rank
NUTX ranks 71 for risk / return — better than 71% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Nutex Health Inc (NUTX) and compare them to a chosen benchmark (S&P 500 Index).
| NUTX | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.88 | 0.90 | -0.01 |
Sortino ratioReturn per unit of downside risk | 1.99 | 1.39 | +0.60 |
Omega ratioGain probability vs. loss probability | 1.24 | 1.21 | +0.03 |
Calmar ratioReturn relative to maximum drawdown | 1.54 | 1.40 | +0.15 |
Martin ratioReturn relative to average drawdown | 2.40 | 6.61 | -4.20 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore NUTX risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Nutex Health Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Nutex Health Inc was 99.93%, occurring on Jul 9, 2024. The portfolio has not yet recovered.
The current Nutex Health Inc drawdown is 98.42%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.93% | Apr 5, 2022 | 567 | Jul 9, 2024 | — | — | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Nutex Health Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Nutex Health Inc is priced in the market compared to other companies in the Health Information Services industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for NUTX, comparing it with other companies in the Health Information Services industry. Currently, NUTX has a P/E ratio of 6.4. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for NUTX compared to other companies in the Health Information Services industry. NUTX currently has a PEG ratio of 0.1. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for NUTX relative to other companies in the Health Information Services industry. Currently, NUTX has a P/S ratio of 0.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |